Phase 1 of HLB Apixaban was approved

By Lee, Seok-Jun | translator Choi HeeYoung

23.01.04 10:03:07

가나다라 0

Expectations for overcoming limitations of existing treatments such as gastrointestinal bleeding 'targeting the 20 trillion won market'

It is predicted that pipelines such as obesity, diabetes, and dementia will be expanded using its own platform

HLB Pharmaceutical has received approval from the Ministry of Food and Drug Safety for phase 1 in Korea, which develops the oral thrombosis treatment Eliquis in the form of a long-term continuous injection (HLBP-024). According to the company on the 4th, HLBP-024 is a treatment developed independently based on HLB Pharmaceutical's long-term continuous injection platform (SMEBR). The company expects that it will be possible to develop various pipelines applying uniform particulate manufacturing technology in the future. The company has already succeeded in transferring long-term continuous injection technology for obesity treatment to the platform.

This clinical trial is the first clinical trial in Korea

Lee, Seok-Jun(wiviwivi@dailypharm.com)

If you want to see the full article, please JOIN US (click)